PMID- 25733317
OWN - NLM
STAT- MEDLINE
DCOM- 20160826
LR  - 20220408
IS  - 1898-018X (Electronic)
IS  - 1898-018X (Linking)
VI  - 22
IP  - 5
DP  - 2015
TI  - Effects of ivabradine therapy on heart failure biomarkers.
PG  - 501-9
LID - 10.5603/CJ.a2015.0012 [doi]
AB  - BACKGROUND: Heart rate (HR) reduction is associated with improved outcomes in 
      patients with heart failure (HF) and biomarkers can be a valuable diagnostic tool 
      in HF management. The primary aim of our study was to evaluate the short-term (6 
      months) effect of ivabradine on N-terminal pro B-type natriuretic peptide 
      (NT-proBNP), CA-125, and cystatin-C values in systolic HF outpatients, and 
      secondary aim was to determine the relationship between baseline HR and the 
      NT-proBNP, CA-125, cystatin-C, and clinical status variation with ivabradine 
      therapy. METHODS: Ninety-eight patients (mean age: 65.81 +/- 10.20 years; 33 men), 
      left ventricular ejection fraction < 35% with Simpson method, New York Heart 
      Association (NYHA) class II-III, sinus rhythm and resting HR > 70/min, optimally 
      treated before the study were included. Among them, two matched groups were 
      formed: the ivabradine group and the control group. Patients received ivabradine 
      with an average (range of 10-15) mg/day during 6 months of follow-up. Blood 
      samples for NT-proBNP, CA-125, and cystatin-C were taken at baseline and at the 
      end of a 6-month follow-up in both groups. RESULTS: There was a significant 
      decrease in NYHA class in the ivabradine group (2.67 +/- +/- 0.47 vs. 1.85 +/- 0.61, p 
      < 0.001). When ivabradine and control groups were compared, a significant 
      difference was also found in NHYA class 6 months later (p = 0.013). A significant 
      decrease was found in HR in the ivabradine and control groups (84.10 +/- 8.76 vs. 
      68.36 +/- +/- 8.32 bpm, p = 0.001; 84.51 +/- 10 vs. 80.40 +/- 8.3 bpm, p = 0.001). When 
      both groups were compared, a significant difference was also found in HR after 6 
      months (p = 0.001). A significant decrease was found in cystatin-C (2.10 +/- 0.73 
      vs. 1.50 +/- 0.44 mg/L, p < 0.001), CA-125 (30.09 +/- 21.08 vs. 13.22 +/- 8.51 U/mL, p 
      < 0.001), and NT-proBNP (1,353.02 +/- 1,453.77 vs. 717.81 +/- 834.76 pg/mL, p < 
      0.001) in the ivabradine group. When ivabradine and control groups were compared 
      after 6 months, a significant decrease was found in all HF parameters 
      (respectively; cystatin-C: p = 0.001, CA-125: p = 0.001, NT-proBNP: p = 0.001). 
      Creatinine level was significantly decreased and glomerular filtration rate (GFR) 
      was significantly increased in the ivabradine group (1.02 +/- 0.26 vs. 0.86 +/- 0.17, 
      creatinine: p = 0.001; 79.26 +/- 18.58 vs. 92.48 +/- 19.88, GFR: p = 0.001). There 
      was no significant correlation between NYHA classes (before and after ivabradine 
      therapy) and biochemical markers, or HR. CONCLUSIONS: In the outpatients with 
      systolic HF, persistent resting HF > 70/min with optimal medical therapy, the 
      NT-proBNP, CA-125, and cystatin-C reductions were obtained with ivabradine 
      treatment. Measurement of NT-proBNP, CA-125, and cystatin-C may prove to be 
      useful in biomarker panels evaluating ivabradine therapy response in HF patients.
FAU - Ordu, Serkan
AU  - Ordu S
FAU - Yildiz, Bekir Serhat
AU  - Yildiz BS
AD  - Pamukkale University Medical Faculty Department of Cardiology. 
      bserhatyildiz@yahoo.com.
FAU - Alihanoglu, Yusuf Izzettin
AU  - Alihanoglu YI
FAU - Ozsoy, Aybars
AU  - Ozsoy A
FAU - Tosun, Mehmet
AU  - Tosun M
FAU - Evrengul, Harun
AU  - Evrengul H
FAU - Kaftan, Havane Asuman
AU  - Kaftan HA
FAU - Ozhan, Hakan
AU  - Ozhan H
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20150303
PL  - Poland
TA  - Cardiol J
JT  - Cardiology journal
JID - 101392712
RN  - 0 (Benzazepines)
RN  - 0 (Biomarkers)
RN  - 0 (CA-125 Antigen)
RN  - 0 (CST3 protein, human)
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Cystatin C)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 3H48L0LPZQ (Ivabradine)
SB  - IM
CIN - Cardiol J. 2015;22(5):482-4. PMID: 26521762
MH  - Aged
MH  - Benzazepines/*therapeutic use
MH  - Biomarkers/blood
MH  - CA-125 Antigen/*blood
MH  - Cardiovascular Agents/*therapeutic use
MH  - Cystatin C/*blood
MH  - Down-Regulation
MH  - Female
MH  - Heart Failure, Systolic/blood/diagnosis/*drug therapy/physiopathology
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Ivabradine
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Peptide Fragments/*blood
MH  - Prospective Studies
MH  - Stroke Volume/drug effects
MH  - Time Factors
MH  - Treatment Outcome
MH  - Turkey
MH  - Ventricular Function, Left/drug effects
OTO - NOTNLM
OT  - CA-125
OT  - NT-proBNP
OT  - cystatin-C
OT  - ivabradine
OT  - systolic heart failure
EDAT- 2015/03/04 06:00
MHDA- 2016/08/27 06:00
CRDT- 2015/03/04 06:00
PHST- 2015/01/14 00:00 [received]
PHST- 2015/01/27 00:00 [accepted]
PHST- 2015/01/25 00:00 [revised]
PHST- 2015/03/04 06:00 [entrez]
PHST- 2015/03/04 06:00 [pubmed]
PHST- 2016/08/27 06:00 [medline]
AID - VM/OJS/J/40791 [pii]
AID - 10.5603/CJ.a2015.0012 [doi]
PST - ppublish
SO  - Cardiol J. 2015;22(5):501-9. doi: 10.5603/CJ.a2015.0012. Epub 2015 Mar 3.